Skip to main content
Home
Latest news
Browse topics
Cardiovascular disorders Chronic kidney disease Diabetes devices & technology GLP-1 receptor agonists Hyperglycemia Hypoglycemia Obesity, diet, & lifestyle interventions SGLT2 inhibitors Type 1 diabetes Type 2 diabetes Browse all topics
EN
EN
In focus
Novel clinical evidence in continuous glucose monitoring Fasting for religion and health in people with diabetes The challenge of type 2 diabetes in children HFpEF & diabetes: Diagnosis and management in the wake of EMPEROR-Preserved Addressing suicide risk in diabetes: Rates and risk factors, HCP fears, and practical advice The SURPASS trials: Summarizing efficacy data on tirzepatide Semaglutide for weight loss: STEP and SELECT trials: Results from the STEP and SELECT trials Why psychosocial care matters DiRECT: Type 2 diabetes remission through weight management
Congress coverage
EASD 58th Annual Meeting 2022 The American Diabetes Association 82nd Scientific Sessions
About us
Medicine Matters Diabetes
EXTENDED SEARCH

06-28-2021 | ADA 2021 | Conference coverage | Video

SURPASS-2: Tirzepatide versus semaglutide in people with type 2 diabetes

Juan Pablo Frías explains the significance of the SURPASS-2 findings, in which the dual agonist tirzepatide provided superior glycemic control and weight loss to semaglutide (5:44).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

06-26-2021 | ADA 2021 | Conference coverage | News

SURPASS-1: Tirzepatide has ‘potent’ glucose-lowering and weight loss efficacy

06-26-2021 | ADA 2021 | Conference coverage | News

SURPASS-3: Tirzepatide proves better option than degludec for type 2 diabetes

06-27-2021 | ADA 2021 | Conference coverage | News

SURPASS-5: Glycemic, weight benefits of tirzepatide in insulin-dependent type 2 diabetes

10-14-2020 | Tirzepatide | At a glance | Article

A quick guide to the SURPASS and SURMOUNT trials
Phase 3 and 4 trials of tirzepatide in type 2 diabetes and obesity

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video
Image Credits